US Bancorp
PHAT icon

US Bancorp’s Phathom Pharmaceuticals PHAT Stock Holding History

US Bancorp’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.28K Buy
295
+18
+6% +$227 ﹤0.01% 3694
2025
Q4 		$4.59K Sell
277
-7,000
-96% -$100K ﹤0.01% 3565
2025
Q3 		$85.7K Buy
7,277
+7,000
+2,527% +$72.2K ﹤0.01% 2413
2025
Q2 		$2.66K Sell
277
-23,486
-99% -$130K ﹤0.01% 3809
2025
Q1 		$149K Buy
23,763
+16,937
+248% +$103K ﹤0.01% 2179
2024
Q4 		$55.4K Buy
6,826
+1,578
+30% +$19.5K ﹤0.01% 2686
2024
Q3 		$94.9K Buy
5,248
+1,166
+29% +$16.3K ﹤0.01% 2415
2024
Q2 		$42K Buy
4,082
+632
+18% +$6.51K ﹤0.01% 2760
2024
Q1 		$36.6K Buy
+3,450
New +$29.3K ﹤0.01% 2847
2023
Q4 		– Sell
-113
Closed -$1.17K – 4107
2023
Q3 		$1.17K Hold
113
– – ﹤0.01% 3742
2023
Q2 		$1.62K Buy
+113
New +$1.3K ﹤0.01% 3732
2023
Q1 		– Sell
-349
Closed -$3.92K – 4179
2022
Q4 		$3.92K Sell
349
-60
-15% -$619 ﹤0.01% 3598
2022
Q3 		$5K Buy
409
+291
+247% +$2.77K ﹤0.01% 3607
2022
Q2 		$1K Sell
118
-113
-49% -$1.16K ﹤0.01% 3989
2022
Q1 		$3K Sell
231
-462
-67% -$7.46K ﹤0.01% 3761
2021
Q4 		$14K Buy
693
+639
+1,183% +$15K ﹤0.01% 3299
2021
Q3 		$2K Buy
54
+37
+218% +$1.23K ﹤0.01% 3906
2021
Q2 		$1K Buy
+17
New +$609 ﹤0.01% 3929

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

US Bancorp's PHAT Position: Q1 2026 in Review

US Bancorp increased its Phathom Pharmaceuticals (PHAT) stake by 6.5% in Q1 2026, buying an estimated $227 and bringing the position to 295 shares worth $3.28K. The position accounts for ﹤0.01% of the portfolio, ranked #3694.

US Bancorp first reported a position in PHAT in Q2 2021 and has held it in 18 quarters since. The position peaked at $149K in Q1 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • US Bancorp held 295 shares of Phathom Pharmaceuticals worth $3.28K as of Q1 2026.
  • US Bancorp bought 18 Phathom Pharmaceuticals shares in Q1 2026, an estimated $227.
  • Phathom Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3694 holding.
  • US Bancorp first reported a position in Phathom Pharmaceuticals in Q2 2021 and has held it in 18 quarters since.
  • US Bancorp's Phathom Pharmaceuticals position peaked at $149K in Q1 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.